RBC Capital Maintains Outperform on Abbott Laboratories, Lowers Price Target to $125
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Shagun Singh maintains an Outperform rating on Abbott Laboratories (ABT) but lowers the price target from $128 to $125.

April 18, 2024 | 3:54 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital maintains an Outperform rating on Abbott Laboratories but lowers the price target from $128 to $125.
The adjustment in price target by RBC Capital, while maintaining an Outperform rating, suggests a continued positive outlook on ABT but with a slightly moderated growth expectation. This could lead to a neutral short-term impact on the stock as the market digests the slight reduction in the price target against the backdrop of an overall positive rating.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100